Health Catalyst (HCAT) Tops Q4 EPS by 8c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance

Health Catalyst (NASDAQ: HCAT) reported Q4 EPS of ($0.21), $0.08 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $43.5 million versus the consensus estimate of $41.71 million.

“We concluded an exceptional year for Health Catalyst on a high note in the fourth quarter of 2019, achieving strong results across all areas of our business and exceeded the midpoint of our guidance for the quarter,” said Dan Burton, CEO of Health Catalyst. “In addition to this financial and operational execution, I was particularly pleased to see that our team member engagement scores, as measured by Gallup, were well in to the 99th percentile and marked the highest achievement in the history of our company. We feel confident that our momentum from 2019 will continue into 2020 and enable us to achieve strong financial and operational results in a manner that is consistent with our mission.”

GUIDANCE:

Health Catalyst sees Q1 2020 revenue of $42-45 million, versus the consensus of $42.95 million.

Health Catalyst sees FY2020 revenue of $185-188 million, versus the consensus of $186.28 million.

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the first-quarter of 2020, we expect:

• Total revenue between $42.0 million and $45.0 million, and
• Adjusted EBITDA between $(8.5) million and $(6.5) million

For the full-year of 2020, we expect:

• Total revenue between $185.0 million and $188.0 million, and
• Adjusted EBITDA between $(23.5) million and $(20.5) million

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Kroger (KR) Tops Q1 EPS by 4c, Misses on Revenue; Offers FY26 Guidance
• Sagtec Global (SAGT) Finalizes Strategic AI Acquisition to Accelerate SaaS Revenue and Multi-Sector AI Deployment
• Jabil (JBL) Tops Q3 EPS by 26c, Beats on Revenue; Offers Q4 Guidance